ProKidney Corp. Skyrockets 515% on Trial Data, But is it a Buy?
Shares of ProKidney Corp. (NASDAQ: PROK) soared 515% on Tuesday, triggering shockwaves across Wall Street after the company unveiled highly promising Phase 2 trial results for its experimental kidney disease...